Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study)

@article{Takada2014SurvivalOH,
  title={Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study)},
  author={Masahiro Takada and Hiroshi Ishiguro and Shigenori Nagai and Shoichiro Ohtani and Hidetaka Kawabata and Yasuhiro Yanagita and Yasuo Hozumi and Chikako Shimizu and Sonsin Takao and Nobuaki Sato and Yoichi Kosaka and Yoshiaki Sagara and Hiroji Iwata and Shinji Ohno and Katsumasa Kuroi and Norikazu Masuda and Hiroyasu Yamashiro and Masahiro Sugimoto and Masahide Kondo and Yoichi Naito and Hironobu Sasano and Takashi Inamoto and Satoshi Morita and Masakazu Toi},
  journal={Breast Cancer Research and Treatment},
  year={2014},
  volume={145},
  pages={143-153}
}
We investigated the disease-free survival (DFS) of HER2-positive primary breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab, as well as predictive factors for DFS and pathologic response. Data from 829 female patients treated between 2001 and 2010 were collected from 38 institutions in Japan. Predictive factors were evaluated using multivariate analyses. The 3-year DFS rate was 87 % [95 % confidence interval (CI) 85–90]. The pathologic complete response (pCR: ypT0/is… CONTINUE READING
10 Extracted Citations
24 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 10 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 24 references

Similar Papers

Loading similar papers…